| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| J G Rasmusse. Drug treatments for schizophrenia - past, present and future. International journal of psychiatry in clinical practice. vol 1. issue 4. 2014-06-21. PMID:24946188. |
the first atypical antipsychotic, clozapine, has been restricted to use in treatment-resistant schizophrenia because of an association with agranwlocytosis. |
2014-06-21 |
2023-08-13 |
Not clear |
| G Joffe, J Rybak, M Burkin, D Burkin, B Appelberg, M Joffe, R Gädeke, R Rimo. Clozapine response in early treatment-resistant schizophrenia. International journal of psychiatry in clinical practice. vol 1. issue 4. 2014-06-21. PMID:24946192. |
clozapine response in early treatment-resistant schizophrenia. |
2014-06-21 |
2023-08-13 |
Not clear |
| Pei-Xian Mao, Yi-Lang Tang, Zhi-Min Wang, Feng Jiang, Charles F Gillespie, Zhuo-Ji Ca. Antipsychotic drug use in 503 Chinese inpatients with schizophrenia. International journal of psychiatry in clinical practice. vol 11. issue 1. 2014-06-20. PMID:24941273. |
conventional antipsychotics and clozapine constitute the current mainstream of schizophrenia treatment in china where a lower percentage of patients receive sgas other than clozapine than in developed countries. |
2014-06-20 |
2023-08-13 |
Not clear |
| b' J Hor\\xc3\\xa1\\xc4\\x8dek J Libiger C H\\xc3\\xb6schl K Borzova I Hendrychov\\xc3\\xa. Clozapine-induced concordant agranulocytosis in monozygotic twins. International journal of psychiatry in clinical practice. vol 5. issue 1. 2014-06-19. PMID:24937002.' |
our case report of twins afflicted synchronously with schizophrenia and later with agranulocytosis after clozapine is of interest because it suggests that genetic factors may participate not only in timing of onset of schizophrenia, but also in the emergence and timing of agranulocytosis in response to clozapine treatment. |
2014-06-19 |
2023-08-13 |
Not clear |
| Wai Hong Man, Maarten Ten Berg, Ingeborg Wilting, Albert Huisman, Wiepke Cahn, Jan Willem Douma, Hanneke den Breeijen, Eibert R Heerdink, Toine Egberts, Wouter van Soling. Fluorescence of neutrophil granulocytes as a biomarker for clozapine use. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 23. issue 11. 2014-06-17. PMID:24074821. |
non-adherence to medication is a major issue in the treatment of schizophrenia in general and in particular for those treated with clozapine. |
2014-06-17 |
2023-08-12 |
Not clear |
| M V Cheine, K Wahlbeck, M Rimó. Pharmacological treatment of schizophrenia resistant to first-line treatment: a critical systematic review and meta-analysis. International journal of psychiatry in clinical practice. vol 3. issue 3. 2014-06-17. PMID:24927201. |
on the basis of the methodologically sound studies included, we conclude that only clozapine has proved to be clinically effective in the treatment of refractory schizophrenia. |
2014-06-17 |
2023-08-13 |
Not clear |
| Giuseppe Guaiana, Philip Tyson, Ann Margaret Mortime. The Rivermead Behavioural Memory Test can predict social functioning among schizophrenic patients treated with clozapine. International journal of psychiatry in clinical practice. vol 8. issue 4. 2014-06-17. PMID:24930553. |
objective the aim of this study was to find out whether clinical symptoms, such as positive and negative symptoms, or cognitive problems, such as impairment in memory, are predictive of social outcome among patients with schizophrenia and treated with clozapine in the long-term. |
2014-06-17 |
2023-08-13 |
human |
| Giuseppe Guaiana, Philip Tyson, Ann Margaret Mortime. The Rivermead Behavioural Memory Test can predict social functioning among schizophrenic patients treated with clozapine. International journal of psychiatry in clinical practice. vol 8. issue 4. 2014-06-17. PMID:24930553. |
methods twelve subjects with a dsm-iii-r diagnosis of schizophrenia treated with clozapine were recruited from an inpatient rehabilitation psychiatry unit. |
2014-06-17 |
2023-08-13 |
human |
| R M Balen, R M Procyshy. Valproic acid for seizure prophylaxis during clozapine therapy: Where's the evidence? International journal of psychiatry in clinical practice. vol 3. issue 4. 2014-06-14. PMID:24921227. |
clozapine, a dibenzodiazepine derivative, is the prototype atypical antipsychotic indicated for treatment-resistant patients with schizophrenia. |
2014-06-14 |
2023-08-13 |
Not clear |
| S Mennickent, A Sobarzo, M Vega, M de Diego, G Godoy, P Rioseco, L Saavedr. Determination of clozapine in serum of patients with schizophrenia as a measurement of medication compliance. International journal of psychiatry in clinical practice. vol 14. issue 1. 2014-06-12. PMID:24917231. |
determination of clozapine in serum of patients with schizophrenia as a measurement of medication compliance. |
2014-06-12 |
2023-08-13 |
human |
| Jun Cai, Wen Zhang, Zhenghui Yi, Weihong Lu, Zhiguo Wu, Jun Chen, Shunying Yu, Yiru Fang, Chen Zhan. Influence of polymorphisms in genes SLC1A1, GRIN2B, and GRIK2 on clozapine-induced obsessive-compulsive symptoms. Psychopharmacology. vol 230. issue 1. 2014-06-10. PMID:23660601. |
clinical observations indicate that atypical antipsychotics, especially clozapine, induce obsessive-compulsive (oc) symptoms in schizophrenia patients. |
2014-06-10 |
2023-08-12 |
Not clear |
| Yasuhiro Kaneda, Karuna Jayathilak, Herbert Meltze. Determinants of work outcome in neuroleptic-resistant schizophrenia and schizoaffective disorder: cognitive impairment and clozapine treatment. Psychiatry research. vol 178. issue 1. 2014-06-03. PMID:20452677. |
determinants of work outcome in neuroleptic-resistant schizophrenia and schizoaffective disorder: cognitive impairment and clozapine treatment. |
2014-06-03 |
2023-08-12 |
human |
| Yasuhiro Kaneda, Karuna Jayathilak, Herbert Meltze. Determinants of work outcome in neuroleptic-resistant schizophrenia and schizoaffective disorder: cognitive impairment and clozapine treatment. Psychiatry research. vol 178. issue 1. 2014-06-03. PMID:20452677. |
data from a prospective longitudinal study was used to test the hypotheses that (1) clozapine treatment would improve employment outcome in treatment-resistant schizophrenia or schizoaffective disorder patients, and (2) specific cognitive functioning at baseline and after treatment would predict work status at baseline and change in work status. |
2014-06-03 |
2023-08-12 |
human |
| Jayita K Deodhar, Kumar Prabhash, Jai P Agarwal, Pankaj Chaturved. Clozapine and cancer treatment: Adding to the experience and evidence. Indian journal of psychiatry. vol 56. issue 2. 2014-06-03. PMID:24891711. |
the judiciousness of the use of clozapine in patients with schizophrenia in clinical practice is brought to an even sharper focus when it has to be used in combination with other agents that cause myelosuppression, for example, chemotherapy and radiation treatment. |
2014-06-03 |
2023-08-13 |
Not clear |
| Yael Midbari, Tanya Ebert, Ira Kosov, Moshe Kotler, Abraham Weizman, Anca Ra. Hematological and cardiometabolic safety of clozapine in the treatment of very early onset schizophrenia: a retrospective chart review. Journal of child and adolescent psychopharmacology. vol 23. issue 8. 2014-05-26. PMID:24111981. |
hematological and cardiometabolic safety of clozapine in the treatment of very early onset schizophrenia: a retrospective chart review. |
2014-05-26 |
2023-08-12 |
Not clear |
| Yael Midbari, Tanya Ebert, Ira Kosov, Moshe Kotler, Abraham Weizman, Anca Ra. Hematological and cardiometabolic safety of clozapine in the treatment of very early onset schizophrenia: a retrospective chart review. Journal of child and adolescent psychopharmacology. vol 23. issue 8. 2014-05-26. PMID:24111981. |
in this retrospective chart review, we compared the safety of clozapine--as determined by hematological and cardiometabolic changes - to that of non-clozapine antipsychotics used in the treatment of childhood-onset schizophrenia (cos). |
2014-05-26 |
2023-08-12 |
Not clear |
| Josiane Bourque, Nadia Lakis, Julie Champagne, Emmanuel Stip, Pierre Lalonde, Olivier Lipp, Adrianna Mendre. Clozapine and visuospatial processing in treatment-resistant schizophrenia. Cognitive neuropsychiatry. vol 18. issue 6. 2014-05-21. PMID:23343453. |
clozapine and visuospatial processing in treatment-resistant schizophrenia. |
2014-05-21 |
2023-08-12 |
human |
| Yi Zhang, Meijuan Chen, Zhiguo Wu, Jun Chen, Shunying Yu, Yiru Fang, Chen Zhan. Association study of Val66Met polymorphism in brain-derived neurotrophic factor gene with clozapine-induced metabolic syndrome: preliminary results. PloS one. vol 8. issue 8. 2014-05-14. PMID:23967328. |
a total of 199 schizophrenia patients being treated with clozapine were divided into two groups, mets and non-mets, based on the diagnostic criteria of the national cholesterol education program's adult treatment panel iii. |
2014-05-14 |
2023-08-12 |
Not clear |
| Eric Latimer, Willy Wynant, Robin Clark, Ashok Malla, Erica Moodie, Robyn Tamblyn, Adonia Naid. Underprescribing of clozapine and unexplained variation in use across hospitals and regions in the Canadian province of Québec. Clinical schizophrenia & related psychoses. vol 7. issue 1. 2014-05-12. PMID:23367500. |
clozapine remains the antipsychotic of choice for people who, having met the criteria for a diagnosis of schizophrenia or a related psychotic disorder, do not respond adequately to other antipsychotic medications. |
2014-05-12 |
2023-08-12 |
Not clear |
| Fabiana Barzotti Kohlrausc. Pharmacogenetics in schizophrenia: a review of clozapine studies. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). vol 35. issue 3. 2014-05-07. PMID:24142094. |
pharmacogenetics in schizophrenia: a review of clozapine studies. |
2014-05-07 |
2023-08-12 |
Not clear |